Why Johnson & Johnson is paying $1bn for Firefly Bio’s cancer drug platform
Johnson & Johnson is chasing the next cancer drug platform. Firefly Bio adds promise, but clinical proof remains the real test.
Why Johnson & Johnson’s lupus and Sjögren’s data matter beyond one Phase 2 readout
See how Johnson & Johnson’s nipocalimab data could reshape lupus and Sjögren’s disease treatment strategy today!
Is atypical EGFR-mutated NSCLC becoming Johnson & Johnson’s next precision oncology battleground?
Atypical EGFR lung cancer lacks clear first-line answers. Rybrevant plus Lazcluze may change that, but trial size still matters.
Can Tremfya turn radiographic evidence into a commercial advantage for Johnson & Johnson?
Find out how Johnson & Johnson’s Tremfya label expansion could reshape IL-23 competition in psoriatic arthritis care.
Why DePuy Synthes’ Gemtrack deal could reshape navigation in hip, knee and shoulder surgery
DePuy Synthes wants to remove a robotics bottleneck. Its Gemtrack deal could change joint surgery navigation if regulators agree.
Johnson & Johnson clears a key OTTAVA hurdle, but the harder robotics test comes next
Robotic surgery is opening up. Johnson & Johnson’s OTTAVA data may test whether hospitals want a new soft tissue platform.
Can Contineum Therapeutics’ PIPE-791 become more than an IPF drug after fresh pain data?
Contineum Therapeutics advances PIPE-791 in IPF and chronic pain while extending cash runway into 2029. Find out what comes next.
Johnson & Johnson’s CAPLYTA update raises the bar for long-term schizophrenia stability
Schizophrenia drugs face a durability test. CAPLYTA’s FDA update gives Johnson & Johnson a stronger long-term stability story.
Why Pulse Biosciences’ 12-month nsPFA data matters in a PFA market dominated by Farapulse and Affera
Boston Scientific owns the PFA market. Pulse Biosciences just posted 90% one-year AF freedom. Is nanosecond PFA a real disruption or an acquisition target?
Can CARTOSOUND SONATA help Johnson & Johnson tighten its grip on electrophysiology workflow?
See how Johnson & Johnson is using CARTOSOUND SONATA and VARIPULSE to reshape electrophysiology workflow and arrhythmia care. Read more.